MDACC Study No:2007-0039 ( NCT No: NCT00778375)
Title:Clofarabine plus Low-Dose Cytarabine Induction Followed by Consolidation of Clofarabine plus Low-Dose Cytarabine Alternating with Decitabine in Frontline AML and High-Risk MDS
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Clofarabine; Cytarabine; Decitabine
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if clofarabine given in
combination with cytarabine and decitabine can help to control the disease in
patients with AML or MDS who are 60 years old or older. The safety of this
treatment will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Clofarabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:Up to 5 weeks during induction. Patients will be admitted to the protective
environment for this time.
Supported By:N/A
Return Visit:Prior to each course of therapy.
Home Care:Therapy will be administered at MDACC. Patients may receive further follow up
at home (e.g. laboratory follow up evaluations, transfusions of blood products
as and if needed, management of infectious complications etc.)

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults